Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Dec 3, 2012
Clinical News

Aclasta: Phase III data

BioCentury | Jun 7, 2012
Distillery Therapeutics

Indication: Cancer

BioCentury | Apr 30, 2012
Clinical News

Aclasta: Postmarketing study started

BioCentury | Jan 2, 2012
Clinical News

Aclasta regulatory update

BioCentury | Oct 10, 2011
Clinical News

Forteo musculoskeletal data

BioCentury | Oct 3, 2011
Clinical News

Aclasta: Additional Phase III data

BioCentury | Sep 12, 2011
Clinical News

Aclasta regulatory update

BioCentury | Sep 12, 2011
Clinical News

Actonel risedronate regulatory update

BioCentury | Jul 25, 2011
Clinical News

Actonel risedronate regulatory update

BioCentury | May 9, 2011
Clinical News

Aclasta regulatory update

Items per page:
1 - 10 of 41